down-arrowleft-arrowright-arrow

Howard P. Ng, Ph.D. Scientific Advisor

Dr. Ng is an experienced scientific advisor who provides unparalleled litigation support for pharmaceutical and biotechnology clients. Drawing on 15 years of experience in drug discovery for companies ranging from big pharma to small start-ups, Dr. Ng possesses expertise in all aspects of drug discovery and development.

LOCATION

New York

+1.212.588.0800

745 Fifth Avenue, 10th Floor,
New York, NY 10151

VIEW IN MAPS
  • Howard Ng is a scientific advisor in the firm’s New York office. Dr. Ng received a Ph.D. in chemistry from Harvard University and has over 15 years of experience leading scientific teams to discover new treatments for areas of high unmet medical need including cancer, auto-immune disorders (multiple sclerosis, rheumatoid arthritis, and psoriasis), cardiovascular disease (stroke), and non-opioid treatment of chronic pain. He is a distinguished scientist with 19 scientific publications in prestigious international journals and 68 issued US patents.
  • Dr. Ng has also provided support for patent litigations and arbitrations as well as Section 337 actions for two of the top five pharmaceutical companies and a top agrochemical company. He has experience in patent prosecution and opinion work including non-infringement, patentability and invalidity analyses.
  • "Structure Function Differences in Nonpeptide CCR1 Antagonists for Human and Mouse CCR1" J. Onuffer, M. A. McCarrick, L. Dunning, M. Liang, M. Rosser, G.-P. Wei, H. Ng, R. Horuk, J. Immunology 2003, 170, 1910-1916.
  • "Automated Parallel Solid-Phase Synthesis of Non-Peptide CCR1 Receptor Antagonists" B. O. Buckman, A. Ghannam, A. Li, M. Liang, R. Mohan, H. P. Ng, Combinatorial Chemistry & High Throughput Screening 2002, 5, 249-251.
  • "Design, Synthesis, and Activity of a Novel Series of Factor Xa Inhibitors: Optimization of Arylamidine Groups" G. Phillips, W. J. Guilford, B. O. Buckman, D. D. Davey, K. A. Eagen, S. Koovakkat, A. Liang, M. McCarrick, R. Mohan, H. P. Ng, M. Pinkerton, B. Subramanyam, E. Ho, , L. Trinh, M. Whitlow, S. Wu, W. Xu, M. M. Morrissey, J. Med. Chem. 2002, 45, 2484-2493.
  • "Design, Synthesis, and Biological Activity of Novel Factor Xa Inhibitors: 4-Aryloxy Substituents of 2,6-Diphenoxypyridines" H. P. Ng, B. O. Buckman, K. A. Eagen, W. J. Guilford, M. J. Kochanny, R. Mohan, K. J. Shaw, S. C., Wu, D. Lentz, A. Liang, L. Trinh, E. Ho, D. Smith, B. Subramanyam, R. Vergona, J. Walters, K. A. White, M. E. Sullivan, M. M. Morrissey, G. B. Phillips, Bioorg. Med. Chem. 2002, 10, 657-666.
  • "CCR1-Specific Non-peptide Antagonist: Efficacy in a Rabbit Allograft Rejection Model" R. Horuk, S. Shurey, H. P. Ng, K. May, J. G. Bauman, I. Islam, B. Buckman, G.-P. Wei, W. Xu, M. Liang, M. Rosser, L. Dunning, J. Hesselgesser, R. H. Snider, M. M. Morrissey, H. D. Perez, C. Green Immunol. Lett. 2001, 76(3), 193-201.
  • "A Non-peptide Functional Antagonist of the CCR1 Chemokine Receptor is Effective in Rat Heart Transplant Rejection" R. Horuk, C. Clayberger, A. M. Krensky, Z. Wang, H.-J. Groene, C. Weber, K. S. C. Weber, P. J. Nelsen, K. May, M. Rosser, L. Dunning, M. Liang, B. Buckman, A. Ghannam, H. P. Ng, I. Islam, J. G. Bauman, G.-P. Wei, S. Monahan, W. Xu, R. H. Snider, M. M. Morrissey, J. Hesselgesser, H. D. Perez, J. Biol. Chem. 2001, 276, 4199-4204.
  • "Identification and Characterization of a Potent, Selective, and Orally ActiveAntagonist of the CC Chemokine Receptor-1" M. Liang, C. Mallari, M. Rosser, H. P. Ng, K. May, S. Monahan, J. G. Bauman, I. Islam, A. Ghannam, B. Buckman, K. Shaw, G.-P. Wei, W. Xu, Z. Zhao, E. Ho, J. Shen, H. Oanh, B. Subramanyam, R. Vergona, D. Taub, L. Dunning, S. Harvey, R. H. Snider, J. Hesselgesser, M. M. Morrissey, H. D. Perez, R. Horuk J. Biol. Chem. 2000, 275, 19000-19008.
  • "Discovery of Novel Non-peptide CCR1 Receptor Antagonists" H.P. Ng; K. May, J. G. Bauman, A. Ghannam, I. Islam, M. Liang, R. Horuk; J. Hesselgesser, R. M. Snider, H. D. Perez, M. M. Morrissey Chemtracts 2000, 13(7), 435-438 (review).
  • "Chemokine Receptor Antagonists" R. Horuk and H. P. Ng Med. Res. Rev. 2000, 20, 155-168 (review).
  • "Species Selectivity of a Small Molecule Antagonist of the CCR1 Chemokine Receptor" M. Liang, M. Rosser, H. P. Ng, K. May, J. G. Bauman, I. Islam, A. Ghannam, P. J. Kretschmer, H. Pu, L. Dunning, R. M. Snider, M. M. Morrissey, J. Hesselgesser, H. D. Perez, R. Horuk Eur. J. Pharm. 2000, 389, 41-49.
  • "Discovery of Novel Non-Peptide CCR1 Receptor Antagonists" H. P. Ng, K. May, J. G. Bauman, A. Ghannam, I. Islam, M. Liang, R. Horuk, J. Hesselgesser, R. M. Snider, H. D. Perez, M. M. Morrissey J. Med. Chem. 1999, 42, 4680-4694.
  • "The Discovery and Therapeutic Applications of CCR1 Chemokine Receptor Antagonists" R. Horuk and H. P. Ng IDrugs 1999, 2, 418-425 (invited review).
  • "Design, Synthesis, and Activitiy to 2,6-Diphenoxypyridine-DerivedFactor Xa Inhibitors" G. Phillips, D. D. Davey, K. A. Eagen, S. K. Koovakkat, A. Liang, H. P. Ng, M. Pinkerton, L. Trinh, M. Whitlow, A. M. Beatty, M. M. Morrissey J. Med. Chem. 1999, 42, 1749-1756.
  • "The Discovery of N-[2-[5-Amino(imino)methyl]-2-hydroxyphenoxy]-3,5-difluoro-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylglycine (ZK-807834): A Potent, Selective and Orally-Active Inhibitor of Factor Xa" G. Phillips, B. Buckman, D. Davey, K. Eagen, W. Guilford, J. Hinchman, E. Ho, S. Koovakkat, A. Liang, D. Light, R. Mohan, H. P. Ng, J. Post, D. Smith, B. Subramanyam, M. E. Sullivan, L. Trinh, R. Vergona, J. Walters, K. White, M. Whitlow, S. Wu, W. Xu, M. M. Morrissey J. Med. Chem. 1998, 41, 3557-3562.
  • "Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor" J. Hesselgesser, H. P. Ng, M. Liang, W. Zheng, K. May, J. G. Bauman, S. Monahan, I. Islam, G. P. Wei, A. Ghannam, M. Rosser, R. M. Snider, M. M. Morrissey, H. D. Perez, R. Horuk J. Biol. Chem. 1998, 213, 15687-15692.
  • "Total Synthesis of the Macrolide Antibiotic Rutamycin B" D. A. Evans, H. P. Ng, D. L. Rieger J. Am. Chem. Soc., 1993, 115, 11446-11459.
  • "Studies Directed Toward the Synthesis of the Rutamycins. Assemblage of the Polypropionate Region of Rutamycin B" D. A. Evans and H. P. Ng Tetrahedron Lett., 1993, 34, 2229-2232.
  • "Diastereoselective Anti-Aldol Reactions of Chiral Ethyl Ketones. Enantioselective Processes for the Synthesis of Polypropionate Natural Products." D. A. Evans, H. P. Ng, J. S. Clark, D. L. Rieger Tetrahedron, 1992, 48, 2127-2142.
  • "Enantioselective Catalyzed Intramolecular Cyclopropanations of Unsaturated Diazo Carbonyl Compounds." W. G. Dauben, R. T. Hendricks, M. J. Luzzio, H. P. Ng Tetrahedron Lett., 1990, 31, 6969-6972.
  • "Discovery of a Novel Duocarmycin-Tumor-Activated Prodrug Conjugate, CRX-103" American
  • Association for Cancer Research 93rd Annual Meeting, San Francisco, CA (2002)
  • "Discovery of CRX-103, a Novel Duocarmycin-Tumor-Activated Prodrug Conjugate, through Chemical Optimization. In vitro Characterization and Proof of Principle." AACR-NCI-EPRTC International Conference on Molecular Targets and Clinical Therapeutics, Miami Beach, FL (2001)
  • "The Identification of Highly Specific Small Molecule Antagonists of the CCR1 Receptor" 5th International Anti-Inflammatory Summit, Princeton, NJ (1999)
  • "The Identification of Highly Specific Small Molecule Antagonists of the CCR1 Receptor" 26th National Medicinal Chemistry Symposium, Richmond, VA (1998).
  • "Design, Synthesis and Biological Activity of Novel Factor Xa Inhibitors. Aryloxy Substitution at the C-4 Position of the 2,6-Diphenylpyridine Series" 215th American Chemical Society National Meeting, Dallas, TX (1998).
  • "The Identification of Highly Specific Small Molecule Antagonists of the CCR1 Receptor" NMHCC Second International Conference on Chemokines in Disease Models and Pathogenesis, Washington, D. C. (1997).
  • Arthur Michael Graduate Prize (Harvard University)
  • B.S. in Chemistry, University of California at Berkeley
  • Ph.D. in Chemistry, Harvard University
  • Registered to practice before the U.S. Patent and Trademark Office

212-588-0800
hng@haugpartners.com

BAR ADMISSIONS

  • Registered to practice before the U.S. Patent and Trademark Office

Haug Partners LLP
745 Fifth Avenue, 10th Floor,
New York, NY 10151
+1.212.588.0800
haugpartners.com

Howard P. Ng, Ph.D.

Scientific Advisor

HIGHLIGHT

Dr. Ng is an experienced scientific advisor who provides unparalleled litigation support for pharmaceutical and biotechnology clients. Drawing on 15 years of experience in drug discovery for companies ranging from big pharma to small start-ups, Dr. Ng possesses expertise in all aspects of drug discovery and development.

OVERVIEW

Howard Ng is a scientific advisor in the firm’s New York office. Dr. Ng received a Ph.D. in chemistry from Harvard University and has over 15 years of experience leading scientific teams to discover new treatments for areas of high unmet medical need including cancer, auto-immune disorders (multiple sclerosis, rheumatoid arthritis, and psoriasis), cardiovascular disease (stroke), and non-opioid treatment of chronic pain. He is a distinguished scientist with 19 scientific publications in prestigious international journals and 68 issued US patents.

Dr. Ng has also provided support for patent litigations and arbitrations as well as Section 337 actions for two of the top five pharmaceutical companies and a top agrochemical company. He has experience in patent prosecution and opinion work including non-infringement, patentability and invalidity analyses.

PUBLICATIONS

  • "Structure Function Differences in Nonpeptide CCR1 Antagonists for Human and Mouse CCR1" J. Onuffer, M. A. McCarrick, L. Dunning, M. Liang, M. Rosser, G.-P. Wei, H. Ng, R. Horuk, J. Immunology 2003, 170, 1910-1916.
  • "Automated Parallel Solid-Phase Synthesis of Non-Peptide CCR1 Receptor Antagonists" B. O. Buckman, A. Ghannam, A. Li, M. Liang, R. Mohan, H. P. Ng, Combinatorial Chemistry & High Throughput Screening 2002, 5, 249-251.
  • "Design, Synthesis, and Activity of a Novel Series of Factor Xa Inhibitors: Optimization of Arylamidine Groups" G. Phillips, W. J. Guilford, B. O. Buckman, D. D. Davey, K. A. Eagen, S. Koovakkat, A. Liang, M. McCarrick, R. Mohan, H. P. Ng, M. Pinkerton, B. Subramanyam, E. Ho, , L. Trinh, M. Whitlow, S. Wu, W. Xu, M. M. Morrissey, J. Med. Chem. 2002, 45, 2484-2493.
  • "Design, Synthesis, and Biological Activity of Novel Factor Xa Inhibitors: 4-Aryloxy Substituents of 2,6-Diphenoxypyridines" H. P. Ng, B. O. Buckman, K. A. Eagen, W. J. Guilford, M. J. Kochanny, R. Mohan, K. J. Shaw, S. C., Wu, D. Lentz, A. Liang, L. Trinh, E. Ho, D. Smith, B. Subramanyam, R. Vergona, J. Walters, K. A. White, M. E. Sullivan, M. M. Morrissey, G. B. Phillips, Bioorg. Med. Chem. 2002, 10, 657-666.
  • "CCR1-Specific Non-peptide Antagonist: Efficacy in a Rabbit Allograft Rejection Model" R. Horuk, S. Shurey, H. P. Ng, K. May, J. G. Bauman, I. Islam, B. Buckman, G.-P. Wei, W. Xu, M. Liang, M. Rosser, L. Dunning, J. Hesselgesser, R. H. Snider, M. M. Morrissey, H. D. Perez, C. Green Immunol. Lett. 2001, 76(3), 193-201.
  • "A Non-peptide Functional Antagonist of the CCR1 Chemokine Receptor is Effective in Rat Heart Transplant Rejection" R. Horuk, C. Clayberger, A. M. Krensky, Z. Wang, H.-J. Groene, C. Weber, K. S. C. Weber, P. J. Nelsen, K. May, M. Rosser, L. Dunning, M. Liang, B. Buckman, A. Ghannam, H. P. Ng, I. Islam, J. G. Bauman, G.-P. Wei, S. Monahan, W. Xu, R. H. Snider, M. M. Morrissey, J. Hesselgesser, H. D. Perez, J. Biol. Chem. 2001, 276, 4199-4204.
  • "Identification and Characterization of a Potent, Selective, and Orally ActiveAntagonist of the CC Chemokine Receptor-1" M. Liang, C. Mallari, M. Rosser, H. P. Ng, K. May, S. Monahan, J. G. Bauman, I. Islam, A. Ghannam, B. Buckman, K. Shaw, G.-P. Wei, W. Xu, Z. Zhao, E. Ho, J. Shen, H. Oanh, B. Subramanyam, R. Vergona, D. Taub, L. Dunning, S. Harvey, R. H. Snider, J. Hesselgesser, M. M. Morrissey, H. D. Perez, R. Horuk J. Biol. Chem. 2000, 275, 19000-19008.
  • "Discovery of Novel Non-peptide CCR1 Receptor Antagonists" H.P. Ng; K. May, J. G. Bauman, A. Ghannam, I. Islam, M. Liang, R. Horuk; J. Hesselgesser, R. M. Snider, H. D. Perez, M. M. Morrissey Chemtracts 2000, 13(7), 435-438 (review).
  • "Chemokine Receptor Antagonists" R. Horuk and H. P. Ng Med. Res. Rev. 2000, 20, 155-168 (review).
  • "Species Selectivity of a Small Molecule Antagonist of the CCR1 Chemokine Receptor" M. Liang, M. Rosser, H. P. Ng, K. May, J. G. Bauman, I. Islam, A. Ghannam, P. J. Kretschmer, H. Pu, L. Dunning, R. M. Snider, M. M. Morrissey, J. Hesselgesser, H. D. Perez, R. Horuk Eur. J. Pharm. 2000, 389, 41-49.
  • "Discovery of Novel Non-Peptide CCR1 Receptor Antagonists" H. P. Ng, K. May, J. G. Bauman, A. Ghannam, I. Islam, M. Liang, R. Horuk, J. Hesselgesser, R. M. Snider, H. D. Perez, M. M. Morrissey J. Med. Chem. 1999, 42, 4680-4694.
  • "The Discovery and Therapeutic Applications of CCR1 Chemokine Receptor Antagonists" R. Horuk and H. P. Ng IDrugs 1999, 2, 418-425 (invited review).
  • "Design, Synthesis, and Activitiy to 2,6-Diphenoxypyridine-DerivedFactor Xa Inhibitors" G. Phillips, D. D. Davey, K. A. Eagen, S. K. Koovakkat, A. Liang, H. P. Ng, M. Pinkerton, L. Trinh, M. Whitlow, A. M. Beatty, M. M. Morrissey J. Med. Chem. 1999, 42, 1749-1756.
  • "The Discovery of N-[2-[5-Amino(imino)methyl]-2-hydroxyphenoxy]-3,5-difluoro-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylglycine (ZK-807834): A Potent, Selective and Orally-Active Inhibitor of Factor Xa" G. Phillips, B. Buckman, D. Davey, K. Eagen, W. Guilford, J. Hinchman, E. Ho, S. Koovakkat, A. Liang, D. Light, R. Mohan, H. P. Ng, J. Post, D. Smith, B. Subramanyam, M. E. Sullivan, L. Trinh, R. Vergona, J. Walters, K. White, M. Whitlow, S. Wu, W. Xu, M. M. Morrissey J. Med. Chem. 1998, 41, 3557-3562.
  • "Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor" J. Hesselgesser, H. P. Ng, M. Liang, W. Zheng, K. May, J. G. Bauman, S. Monahan, I. Islam, G. P. Wei, A. Ghannam, M. Rosser, R. M. Snider, M. M. Morrissey, H. D. Perez, R. Horuk J. Biol. Chem. 1998, 213, 15687-15692.
  • "Total Synthesis of the Macrolide Antibiotic Rutamycin B" D. A. Evans, H. P. Ng, D. L. Rieger J. Am. Chem. Soc., 1993, 115, 11446-11459.
  • "Studies Directed Toward the Synthesis of the Rutamycins. Assemblage of the Polypropionate Region of Rutamycin B" D. A. Evans and H. P. Ng Tetrahedron Lett., 1993, 34, 2229-2232.
  • "Diastereoselective Anti-Aldol Reactions of Chiral Ethyl Ketones. Enantioselective Processes for the Synthesis of Polypropionate Natural Products." D. A. Evans, H. P. Ng, J. S. Clark, D. L. Rieger Tetrahedron, 1992, 48, 2127-2142.
  • "Enantioselective Catalyzed Intramolecular Cyclopropanations of Unsaturated Diazo Carbonyl Compounds." W. G. Dauben, R. T. Hendricks, M. J. Luzzio, H. P. Ng Tetrahedron Lett., 1990, 31, 6969-6972.

PRESENTATIONS

  • "Discovery of a Novel Duocarmycin-Tumor-Activated Prodrug Conjugate, CRX-103" American
  • Association for Cancer Research 93rd Annual Meeting, San Francisco, CA (2002)
  • "Discovery of CRX-103, a Novel Duocarmycin-Tumor-Activated Prodrug Conjugate, through Chemical Optimization. In vitro Characterization and Proof of Principle." AACR-NCI-EPRTC International Conference on Molecular Targets and Clinical Therapeutics, Miami Beach, FL (2001)
  • "The Identification of Highly Specific Small Molecule Antagonists of the CCR1 Receptor" 5th International Anti-Inflammatory Summit, Princeton, NJ (1999)
  • "The Identification of Highly Specific Small Molecule Antagonists of the CCR1 Receptor" 26th National Medicinal Chemistry Symposium, Richmond, VA (1998).
  • "Design, Synthesis and Biological Activity of Novel Factor Xa Inhibitors. Aryloxy Substitution at the C-4 Position of the 2,6-Diphenylpyridine Series" 215th American Chemical Society National Meeting, Dallas, TX (1998).
  • "The Identification of Highly Specific Small Molecule Antagonists of the CCR1 Receptor" NMHCC Second International Conference on Chemokines in Disease Models and Pathogenesis, Washington, D. C. (1997).

AWARDS

  • Arthur Michael Graduate Prize (Harvard University)

EDUCATION

  • B.S. in Chemistry, University of California at Berkeley
  • Ph.D. in Chemistry, Harvard University

BAR ADMISSIONS

  • Registered to practice before the U.S. Patent and Trademark Office